Antimüllerian hormone: Prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization

Fertility and Sterility

Volumn 104, Issue 4, 2015, Pages 891-898.e2

  Hamdine, Ouijdane ^a   Eijkemans, Marinus J C ^a   Lentjes, Eef G W ^a   Torrance, Helen L ^a   Macklon, Nick S ^a,b   Fauser, Bart C J M ^a   Broekmans, Frank J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

AMH; GnRH antagonist; IVF; live birth

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; GANIRELIX; MUELLERIAN INHIBITING FACTOR; RECOMBINANT FOLLITROPIN; GONADORELIN; HORMONE ANTAGONIST;

ADULT; ARTICLE; BIRTH RATE; BLOOD SAMPLING; COHORT ANALYSIS; CUMULATIVE LIVE BIRTH RATE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HORMONE BLOOD LEVEL; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; LOADING DRUG DOSE; LUTEAL PHASE; MAJOR CLINICAL STUDY; NOMOGRAM; OBSERVATIONAL STUDY; OOCYTE MATURATION; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVULATION INDUCTION; PREDICTION; PREDICTIVE VALUE; PREGNANCY RATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; EPIDEMIOLOGY; INFERTILITY, FEMALE; MALE; PREGNANCY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

ADULT; ANTI-MULLERIAN HORMONE; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INFERTILITY, FEMALE; LIVE BIRTH; MALE; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; PROGNOSIS; RETROSPECTIVE STUDIES; SPERM INJECTIONS, INTRACYTOPLASMIC; TREATMENT OUTCOME;

EID: 84942838883     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2015.06.030     Document Type: Article

References (34)

1. A.M. Lintsen, M.J. Eijkemans, C.C. Hunault, C.A. Bouwmans, L. Hakkaart, J.D. Habbema, and et al. Predicting ongoing pregnancy chances after IVF and ICSI: a national prospective study Hum Reprod 22 2007 2455 2462
2. S.M. Nelson, R.A. Anderson, F.J. Broekmans, N. Raine-Fenning, R. Fleming, and A. la Marca Anti-müllerian hormone: clairvoyance or crystal clear? Hum Reprod 27 2012 631 636
3. T. Brodin, N. Hadziosmanovic, L. Berglund, M. Olovsson, and J. Holte Antimullerian hormone levels are strongly associated with live-birth rates after assisted reproduction J Clin Endocrinol Metab 98 2013 1107 1114
4. A. Hazout, P. Bouchard, D.B. Seifer, P. Aussage, A.M. Junca, and P. Cohen-Bacrie Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol Fertil Steril 82 2004 1323 1329
5. A. la Marca, S.M. Nelson, G. Sighinolfi, M. Manno, E. Baraldi, L. Roli, and et al. Anti-müllerian hormone-based prediction model for a live birth in assisted reproduction Reprod Biomed Online 22 2011 341 349
6. K. Lukaszuk, M. Kunicki, J. Liss, M. Lukaszuk, and G. Jakiel Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization Eur J Obstet Gynecol Reprod Biol 168 2013 173 177
7. K. Majumder, T.A. Gelbaya, I. Laing, and L.G. Nardo The use of anti-müllerian hormone and antral follicle count to predict the potential of oocytes and embryos Eur J Obstet Gynecol Reprod Biol 150 2010 166 170
8. S.M. Nelson, R.W. Yates, and R. Fleming Serum anti-müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy Hum Reprod 22 2007 2414 2421
9. S.L. Broer, J. van Disseldorp, K.A. Broeze, M. Dolleman, B.C. Opmeer, P. Bossuyt, and et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach Hum Reprod Update 19 2013 26 36
10. S. Sahmay, G. Demirayak, O. Guralp, P. Ocal, L.M. Senturk, E. Oral, and et al. Serum antimüllerian hormone, follicle stimulating hormone and antral follicle count measurement can not predict pregnancy rates in IVF/ICSI cycles J Assist Reprod Genet 29 2012 589 595
11. J.M. Smeenk, F.C. Sweep, G.A. Zielhuis, J.A. Kremer, C.M. Thomas, and D.D. Braat Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection Fertil Steril 87 2007 223 226
12. P. Bhide, A. Gudi, A. Shah, P. Timms, K. Grayson, and R. Homburg Anti-müllerian hormone as a predictor of pregnancy following IVF Reprod Biomed Online 26 2013 247 252
13. S. Iliodromiti, T.W. Kelsey, O. Wu, R.A. Anderson, and S.M. Nelson The predictive accuracy of anti-müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature Hum Reprod Update 20 2014 560 570
14. A. Khader, S.M. Lloyd, A. McConnachie, R. Fleming, V. Grisendi, A. la Marca, and et al. External validation of anti-müllerian hormone based prediction of live birth in assisted conception J Ovarian Res 6 2013 3 10
15. H.W. Li, V.C. Lee, E.Y. Lau, W.S. Yeung, P.C. Ho, and E.H. Ng Role of baseline antral follicle count and anti-müllerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis PLoS One 8 2013 e61095
16. D.E. Reichman, D. Goldschlag, and Z. Rosenwaks Value of antimüllerian hormone as a prognostic indicator of in vitro fertilization outcome Fertil Steril 101 2014 1012 1018
17. H.G. Al-Inany, M.A. Youssef, M. Aboulghar, F. Broekmans, M. Sterrenburg, J. Smit, and et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology Cochrane Database Syst Rev 2011 CD001750
18. A.N. Andersen, H. Witjes, K. Gordon, and B. Mannaerts Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment Hum Reprod 26 2011 3413 3423
19. J.C. Arce, A. La Marca, K.B. Mirner, A.A. Nyboe, and R. Fleming Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients Fertil Steril 99 2013 1644 1653
20. O. Hamdine, M.J. Eijkemans, E.W. Lentjes, H.L. Torrance, N.S. Macklon, B.C. Fauser, and et al. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-müllerian hormone Hum Reprod 30 2015 170 178
21. X. Han, M. McShane, R. Sahertian, C. White, and W. Ledger Pre-mixing serum samples with assay buffer is a prerequisite for reproducible anti-müllerian hormone measurement using the Beckman Coulter Gen II assay Hum Reprod 29 2014 1042 1048
22. N. van Geloven, V. van der Veen, P.M. Bossuyt, P.G. Hompes, A.H. Zwinderman, and B.W. Mol Can we distinguish between infertility and subfertility when predicting natural conception in couples with an unfulfilled child wish? Hum Reprod 28 2013 658 665
23. M.J. Pencina, R.B. d'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
24. M.J. Pencina, R.B. d'Agostino, K.M. Pencina, A.C. Janssens, and P. Greenland Interpreting incremental value of markers added to risk prediction models Am J Epidemiol 176 2012 473 481
25. S.K. Sunkara, V. Rittenberg, N. Raine-Fenning, S. Bhattacharya, J. Zamora, and A. Coomarasamy Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles Hum Reprod 26 2011 1768 1774
26. J.C. Arce, A.N. Andersen, M. Fernandez-Sanchez, H. Visnova, E. Bosch, J.A. Garcia-Velasco, and et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection Fertil Steril 102 2014 1633 1640
27. M.D. Sterrenburg, S.M. Veltman-Verhulst, M.J. Eijkemans, E.G. Hughes, N.S. Macklon, F.J. Broekmans, and et al. Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis Hum Reprod Update 17 2011 184 196
28. B. Ata, B. Kaplan, H. Danzer, M. Glassner, M. Opsahl, S.L. Tan, and et al. Array CGH analysis shows that aneuploidy is not related to the number of embryos generated Reprod Biomed Online 24 2012 614 620
29. S.K. Sunkara, Y. Khalaf, A. Maheshwari, P. Seed, and A. Coomarasamy Association between response to ovarian stimulation and miscarriage following IVF: an analysis of 124 351 IVF pregnancies Hum Reprod 29 2014 1218 1224
30. L. van den Wijngaard, M. van Wely, E.A. Dancet, N.M. van Mello, C.A. Koks, V. van der Veen, and et al. Patients' preferences for gonadotrophin-releasing hormone analogs in in vitro fertilization Gynecol Obstet Invest 78 2014 16 21
31. E.R. te Velde, D. Nieboer, A.M. Lintsen, D.D. Braat, M.J. Eijkemans, J.D. Habbema, and et al. Comparison of two models predicting IVF success; the effect of time trends on model performance Hum Reprod 29 2014 57 64
32. S.L. Broer, M. Dolleman, J. van Disseldorp, K.A. Broeze, B.C. Opmeer, P.M. Bossuyt, and et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis Fertil Steril 100 2013 420 429
33. N.P. Polyzos, D. Stoop, C. Blockeel, P. Adriaensen, P. Platteau, E. Anckaert, and et al. Anti-müllerian hormone for the assessment of ovarian response in GnRH-antagonist-treated oocyte donors Reprod Biomed Online 24 2012 532 539
34. N.P. Polyzos, S.M. Nelson, D. Stoop, M. Nwoye, P. Humaidan, E. Anckaert, and et al. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study Fertil Steril 100 2013 438 444